FindMyKOL

Alireza Nami, MD

Basic profile

Rheumatology

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionCharlotte, NC · SoutheastSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Alireza Nami is a Rheumatology/Immunology physician. OpenAlex indexes 6 publications with 1,073 citations (h-index 5).

Overview

Scholarship

indexed output and impact (OpenAlex)
6publications

Publications indexed by OpenAlex. Counts exclude supporting files.

1,073citations

Citations across these publications.

5h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
25companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Janssen
    Program year202515 paymentsResearch
    $156,697
  • AbbVie
    Program year202524 paymentsResearch
    $119,104
  • AstraZeneca
    Program year20251 paymentResearch
    $100,711
All 97 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    49.3%
    RANK Ligand Inhibitor36.2%
    Denosumab99%Prolia1%
    Part D + Part B≥32 patients
    Central alpha-2 Adrenergic Agonist5%
    Tizanidine Hcl100%
    Part D≥106 patients

    + 7 more classes in this area

  • Nervous system

    19.6%
    Gabapentinoids7.4%
    Gabapentin70%Pregabalin30%
    Part D≥113 patients
    SNRI6.3%
    Duloxetine Hcl100%
    Part D≥146 patients

    + 10 more classes in this area

  • Cancer & immunology

    13.5%
    Folate Analog Metabolic Inhibitor8.4%
    Methotrexate sodium47%Methotrexate45%Rasuvo3%Otrexup3%Methotrexate Sodium2%
    Part D + Part B<11 patients
    Antirheumatic Agent1.3%
    Leflunomide100%
    Part D≥30 patients

    + 5 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”